aragen.com

aragen

Formulation Development Solutions

Pre-Formulation Development

Physical form selection

- Crystallisation
- Salt screening
- Co-crystal screening
- Polymorph screening

Oral delivery

- Suspension
- Solution
- Microemulsion
- Solid dispersion
- Nanosuspension

Parenteral delivery

- Solution
- Suspension
- Liposomes
- Microparticles
- In-situ gels

Topical delivery

- Lotion
- Gel
- Cream
- Ointment

Nasal delivery

- Solution
- Suspension
- Emulsion
- Dry powders

Preclinical studies Support

- Efficacy studies
- PK studies
- Exploratory tox studies
- GLP tox studies

Formulation Development and Manufacturing

Tablets
- Immediate Release
- Sustained Release
- Mini
- Bilayer
- Delayed Release
- Colon delivery
- Oral films

Liquids
- Suspension
- Solution
- Emulsion

Parenterals
- Solution
- Suspension
- Lyophilised
- Ophthalmic
- Nebulised
- Vial/Ampule/ Pre-filled Syringe

Capsules
- Powder
- Pellets
- Liquids

Semisolids
- Gel
- Cream
- Ointment
- Lotion

Processes/ Technologies
- Wet Granulation
- Roller Compaction
- Micronisation
- Nanomilling
- Spray Drying
- Fluid Bed Coating
- Tabletting
- Capsule Filling
- Film coating
- Packaging

Novel Drug Delivery System Development (Oral)

Solid Dispersion
For poorly soluble compounds to increase dissolution rate and saturation solubility amorphous drug within a polymer

Microemulsion
Avoid influence of solid form. Increase solubility in GI tract. Compound is completely solubilized

Nanosuspension
For poorly soluble compounds to increase dissolution rate and saturation solubility crystals in nano size range

Novel Drug Delivery System Development (Parenteral)



Parentera
Targeted drug delivery system

Microparticles
Long-acting Injectable microspheres using biodegradable polymers

In Situ Gels
Controlled release of drug using thermo-sensitive polymer gels

Let's begin the conversation

E: bd@aragen.com
W: aragen.com
in /company/aragen-life-sciences
f /AragenLifeSciences

ALXXVIB24

aragen

India • USA • Netherlands • Japan • S Korea